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ABSTRACT
Objectives: The Sight Loss and Vision Priority Setting
Partnership aimed to identify research priorities relating
to sight loss and vision through consultation with
patients, carers and clinicians. These priorities can be
used to inform funding bodies’ decisions and enhance
the case for additional research funding.
Design: Prospective survey with support from the
James Lind Alliance.
Setting: UK-wide National Health Service (NHS) and
non-NHS.
Participants: Patients, carers and eye health
professionals. Academic researchers were excluded
solely from the prioritisation process. The survey was
disseminated by patient groups, professional bodies, at
conferences and through the media, and was available
for completion online, by phone, by post and by
alternative formats (Braille and audio).
Outcome measure: People were asked to submit the
questions about prevention, diagnosis and treatment of
sight loss and eye conditions that they most wanted to
see answered by research. Returned survey questions
were reviewed by a data assessment group. Priorities
were established across eye disease categories at final
workshops.
Results: 2220 people responded generating 4461
submissions. Sixty-five per cent of respondents had
sight loss and/or an eye condition. Following initial
data analysis, 686 submissions remained which
were circulated for interim prioritisation (excluding
cataract and ocular cancer questions) to 446 patients/
carers and 218 professionals. The remaining 346
questions were discussed at final prioritisation
workshops to reach agreement of top questions per
category.
Conclusions: The exercise engaged a diverse
community of stakeholders generating a wide range
of conditions and research questions. Top priority
questions were established across 12 eye disease
categories.
INTRODUCTION
In the UK, it is estimated that almost two
million people are affected by sight loss and
this number is expected to double by 2050.1
Currently 50% of sight loss in the UK is
avoidable, but there are also many unavoid-
able sight loss conditions. Whether it is to
address childhood eye conditions or those
affecting adults, research is needed to
inform us about prevention, to develop new
techniques for early diagnosis, and to
develop new and more effective treatments
for many eye conditions.
The Sight Loss and Vision Priority Setting
Partnership (SLV-PSP) was developed from
earlier work by the Eye Research Group
(ERG) of VISION 2020 UK whose mission is
the elimination of avoidable sight loss and
the amelioration of the effects of sight loss
when it cannot be avoided.2 The UK Vision
Strategy sets out ways of addressing avoidable
sight loss in the UK. There is much that can
be done to improve the nation’s eye health,
and to eliminate avoidable sight loss. There
are however gaps in the evidence base
regarding eye health interventions and the
best way to deliver services. Research is
needed to support the UK Vision Strategy. In
Strengths and limitations of this study
▪ Wide ranging and comprehensive coverage.
▪ Substantial response.
▪ The hardest to reach and those with the least
opportunity to be heard may indeed have not
been heard.
▪ Any such groups now feeling excluded should
have an opportunity to redress this.
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key areas, research is urgently required to enable the
Vision Strategy to be implemented in an evidence-based
way that ensures efﬁcient and effective development.
Despite on-going research in the UK and other coun-
tries, there are still many questions about the prevention,
diagnosis and treatment of sight loss and eye conditions
that remain unanswered. Given that resources for research
are limited, it is important for research funders to under-
stand how patients, carers and eye health professionals pri-
oritise these unanswered questions so that future research
can be consolidated and targeted accordingly.3
The purpose of this project was to undertake a com-
prehensive, UK-wide, survey of patients, carers and clini-
cians to identify research questions and priorities to
inform decisions of funding bodies and enhance the
case for additional research funding.
The priority setting process has been well established
by the James Lind Alliance ( JLA) (http://www.
lindalliance.org/) which has supported partnerships on
a range of topics since 2004. This partnership initiated
by Fight for Sight, the UK’s leading eye research charity
was established with support, ﬁnancial and in kind, from
the College of Optometrists, the Royal College of
Ophthalmologists, the NIHR Moorﬁelds Biomedical
Research Centre, the RNIB, UK Vision Strategy and the
Cochrane Eyes and Vision Group. A representative from
the JLA convened meetings of the steering committee
and provided independent chairmanship for this and
the priority setting workshops. Their extensive experi-
ence in this process ensured no single voice exerted
undue inﬂuence over the prioritisation process and that
the views of patients, their carers and clinicians were
paramount. The views of researchers with no clinical
involvement with patients and views of commercial orga-
nisations were not included in the prioritisation.
METHODS AND MATERIALS
The detailed methods for this prioritisation process have
been described in detail elsewhere.4 In brief, the process
comprised ﬁve stages (ﬁgure 1). Our study did not
require ethical approval or consent from participants.
JLA priority setting partnerships do not require ethical
approval. Dissemination of the survey was via open com-
munications through professional bodies, charities and
related organisations. The survey was not undertaken
through Higher Education Institutes or through
National Health Service (NHS) organisations and does
not recruit NHS patients. The survey contained clear
information on the aims of the priority setting partner-
ship, how the process works and how data will be used.
In addition, submission of questions was anonymised.
For the workshops in which priorities were discussed
and agreed, participants choose to voluntarily attend
and consent was not required for this. We followed the
ethical guidance for participation, information and
evaluation from the JLA guidebook (http://www.
jlaguidebook.org/jla-guidebook.asp?val=56).
Establishing the SLV-PSP
A steering committee and data assessment group com-
prising the authors of this article oversaw the process.
Each member was responsible for contributing to and
managing a part of the process and was selected for
their expertise and association with eye research. The
steering committee also included patient representatives
and eye health professionals. In April 2012, an initial
stakeholder meeting was held to engage the groups and
organisations with member bases and community inﬂu-
ence. This was to ensure that the initial survey would be
disseminated and completed by as many patients, rela-
tives, carers and eye health professionals as possible in
the UK.
Main survey
The SLV-PSP survey was launched on 1 May 2012 and
was open until 31 July 2012. The aim of the survey was
to identify patients’, carers’ and eye health professionals’
unanswered questions about sight loss and eye condi-
tions. The survey’s primary question was “What question
(s) about the prevention, diagnosis and treatment of
sight loss and eye conditions would you like to see
answered by research?”
Data analysis
Following closure of the survey, all submissions were
examined. Out-of-scope submissions were removed
including those not related to the topic and uncertain-
ties better suited to social research. In-scope uncertain-
ties were allocated into disease-speciﬁc groups and
reworded in PICO format (Population, Intervention,
Comparison, Outcome). Searches were then undertaken
to ascertain whether each uncertainty could be answered
by an up-to-date systematic review. All unanswered uncer-
tainties were then allocated to 1 of 12 eye disease cat-
egories, with duplicates removed and similar questions
combined. Checks were also made to identify any
on-going trials, which might address the uncertainty.
The 12 categories were formed following discussions by
the steering group on the most logical and pragmatic
way to organise the data within the time and resources
available.
Interim prioritisation
In order to start reducing the number of uncertainties,
an interim prioritisation exercise was conducted over
email and by post. Patients, carers and eye health profes-
sionals were invited to examine the long lists and then
choose and rank 10 of the uncertainties.
Final prioritisation
The remaining uncertainties were ranked by patients,
carers, relatives, organisation representatives and eye
health professionals in 1-day workshops facilitated by the
JLA, using Nominal Group Technique—a mix of discus-
sion and ranking. For each category, the top 10/11 ques-
tions were agreed.
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RESULTS
Main survey
In response to the survey, 2220 people generated 4461
submissions. Of these respondents, 17% identiﬁed them-
selves as healthcare professionals including primarily
ophthalmologists, optometrists, orthoptists, ophthalmic
nurses, opticians and people working in social care and
rehabilitation services (ﬁgure 2). Over 60% were people
with sight loss or an eye condition. The average age of
survey participants was 65.7 years old (range 16 months
(proxy completion of survey by adult carer) to
105 years). Just under two-thirds (62%) of the respon-
dents were female. The geographical split was England
89%, Scotland 6%, Wales 4% and Northern Ireland 1%.
Data analysis
Following data analysis to remove duplicate/answered/
out of scope uncertainties, 686 uncertainties remained.
These were divided into 12 eye disease categories.
Table 1 shows each category with the initial number of
submissions received after the survey responses were sub-
mitted, the number of uncertainties sent to interim pri-
oritisation, the number of participants at interim
prioritisation and the number of uncertainties consid-
ered at the ﬁnal prioritisation workshops.
Interim prioritisation
Respondents from the initial survey, organisations and
eye healthcare professionals with expertise in the eye
Figure 1 Flow chart showing
the steps of the process from
stage 1 when establishing the
Priority Setting Partnership (PSP)
through to stage 5 at the final
prioritisation (PICO, Population,
Intervention, Comparison,
Outcome).
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diseases in 10 categories were contacted to provide
interim priority rankings. The smaller number of ques-
tions asked in the categories relating to cataract and
ocular cancer meant that an interim prioritisation exer-
cise was not required for either category. A large
response was received for the interim exercise, with
input from 446 patients, carers and relatives plus 218 eye
health professionals. Uncertainties accumulated scores
based on rank and frequency, resulting in short lists of
around 30 uncertainties per category, which were taken
to ﬁnal workshops.
Final prioritisation
In April and May 2013, 12 ﬁnal prioritisation workshops
were held: one for each eye disease category. Balanced
numbers of patients/carers/relatives and eye health pro-
fessionals participated. In total, 155 participants
attended across all 12 workshops: 78 patients and 77
clinicians (table 2). The topics debated at each work-
shop comprised between 19 and 31 questions per cat-
egory. Overall, 153 questions about sight loss and vision
were considered resulting in lists of 10/11 priorities for
each of the 12 categories (table 3). The questions
addressed the broad topics of aetiology, prevention,
identiﬁcation and interventions with the number 1 ques-
tions as follows:
Age-related macular degeneration
1. Can a treatment to stop dry AMD progressing and/or
developing into the wet form be devised?
Cataract
1. How can cataracts be prevented from developing?
Childhood-onset disorders
1. How can cerebral visual impairment be identiﬁed,
prevented and treated in children?
Figure 2 Background of respondents showing that questions
were largely received from people who have sight loss or an
eye condition, but also including eye health professions,
organisations, parents, family and carers.
Table 1 Categories of eye condition
Initial number of
survey questions
Number of questions
at interim
prioritisation
Number of participants
at interim prioritisation
Number of questions
at final prioritisation
Age-related macular
degeneration
763 43 101 PPI
25 Professionals
29
Cataract 191 27 Not required 27
Childhood-onset
disorders
125 69 12 PPI
20 Professionals
30
Corneal and external
diseases
292 93 25 PPI
38 Professionals
30
Glaucoma 1235 78 182 PPI
25 Professionals
30
Inherited retinal diseases 280 63 27 PPI
25 Professionals
30
Neuro-ophthalmology 125 43 15 PPI
21 Professionals
30
Ocular cancer 26 19 Not required 19
Ocular inflammatory
diseases
472 66 27 PPI
21 Professionals
30
Refractive error and
ocular motility
188 70 21 PPI
23 Professionals
31
Retinal vascular
diseases
205 56 15 PPI
12 Professionals
30
Vitreoretinal and ocular
trauma
265 59 21 PPI
8 Professionals
30
Professionals: Inclusive of eye health professions.
Patient and Public Involvement (PPI): Inclusive of patients, carers, relatives, organisation representatives.
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Corneal and external diseases
1. Can new therapies such as gene or stem cell treat-
ments be developed for corneal diseases?
Glaucoma
1. What are the most effective treatments for glaucoma
and how can treatment be improved?
Inherited retinal diseases
1. Can a treatment to slow down progression or reverse
sight loss in inherited retinal diseases be developed?
Neuro-ophthalmology
1. What is the underlying cause of optic nerve damage
in optic neuropathies, such as anterior ischaemic
optic neuropathy, Leber’s hereditary optic neur-
opathy, optic neuritis and other optic neuropathies?
Ocular cancer
1. What can be done to help ocular cancer sufferers?
Ocular inﬂammatory diseases
1. What are the most effective treatments for ocular and
orbital inﬂammatory diseases?
Refractive error and ocular motility
1. What factors inﬂuence the development of refractive
error (myopia, astigmatism, presbyopia and
long-sightedness)?
Retinal vascular diseases
1. What are the best methods to prevent retinopathy of
prematurity?
Vitreoretinal and ocular trauma
1. How can surgical techniques be improved to save
sight for eyes damaged by injury?
DISCUSSION
About 50% of sight loss in the UK is currently avoid-
able.1 Recognising this and the UK’s pre-eminent pos-
ition in eye research, the Vision 2020UK ERG
considered that any UK Research Agenda must look at
addressing unavoidable sight loss for it to be credible.
The challenge was to produce a coherently constructed
and constituted prioritised research agenda whose
methods were clear and for which there had been inclu-
sive and widespread consultation, where everyone with
an interest had been offered the opportunity to contrib-
ute and be heard. As a result of this priority setting part-
nership, we have established top 10 lists of research
questions for a range of eye conditions.
There are a number of strengths to this study. The
SLV-PSP is unique because it sought the combined views
of patients, carers and eye health professionals to identify
uncertainties about the prevention, diagnosis and treat-
ment of sight loss and eye conditions and prioritise them
for research to address.5 It is rare that those with direct
experience of conditions are able to inﬂuence the
research agenda.3 5 6 The views of patients, carers and pro-
fessionals were given equal merit. All submitted questions
were evaluated independently and equally. Duplicate ques-
tions and out-of-scope questions were removed. We did
not encounter particular misunderstandings between lay-
persons and professionals or insufﬁcient knowledge of the
public. Open discussions occurred during the face-to-face
workshops with good communication and facilitation to
encourage respectful listening in accordance with JLA
guidelines. Questions could only be pooled if this was
agreed by patients, carers and professionals. Where there
was no agreement, the questions remained separate. Thus,
any differing perspectives of priorities between partici-
pants were acknowledged. We did not aim to compare and
contrast questions from patients, carers and professionals
but to represent and act on all.
This SLV-PSP provided an extensive set of unanswered
questions prioritised by patients, carers and eye health
professionals across 12 categories of eye conditions.
These questions addressed a broad range of eye condi-
tions and considered issues of aetiology, prevention,
screening, assessment and management. Importantly,
the public were as likely to propose questions in relation
to aetiology, assessment and management just as profes-
sionals were as likely to raise questions regarding impact
of sight loss.
Table 2 Final workshop participants
Category
Total number
of workshop
participants
Number of patients,
relatives, carers, patient
groups and organisations
Number of
eye health
professionals
Age-related macular degeneration 17 9 8
Cataract 11 5 6
Childhood-onset disorders 16 7 9
Corneal and external diseases 12 5 7
Glaucoma 17 9 8
Inherited retinal diseases 19 11 8
Neuro-ophthalmology 10 6 4
Ocular cancer 10 6 4
Ocular inflammatory diseases 10 5 5
Refractive error and ocular motility 12 5 7
Retinal vascular diseases 11 3 8
Vitreoretinal and ocular trauma 10 7 3
Total 155 78 77
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Table 3 Top 10 lists per category
Age-related macular
degeneration Cataract
Childhood-onset
disorders Corneal and external diseases Glaucoma
Inherited retinal
diseases
1 Can a treatment to
stop dry AMD
progressing and/or
developing into the
wet form be devised?
How can cataracts be
prevented from
developing?
How can cerebral visual
impairment be identified,
prevented and treated in
children?
Can new therapies such as gene
or stem cell treatments be
developed for corneal diseases?
What are the most
effective treatments
for glaucoma and how
can treatment be
improved?
Can a treatment to slow
down progression or
reverse sight loss in
inherited retinal
diseases be
developed?
2 What is the cause of
AMD?
Can the return of cloudy
or blurred vision after
cataract surgery known
as posterior capsule
opacity (PCO) or
secondary cataract be
prevented?
How can treatment for
visual pathway damage
associated with preterm
birth be developed?
What is the most effective
management for dry eye and can
new strategies be developed?
How can loss of vision
be restored for people
with glaucoma?
How can sight loss be
prevented in an
individual with inherited
retinal disease?
3 How can AMD be
prevented?
How can cataract
progression be slowed
down?
How do we improve
screening and
surveillance from the
antenatal period through
to childhood to ensure
early diagnosis of
impaired vision and eye
conditions?
Can treatments to save eye sight
from microbial keratitis be
improved?
How can glaucoma be
stopped from
progressing?
Is a genetic (molecular)
diagnosis possible for
all inherited retinal
diseases?
4 Are there ways of
restoring sight loss for
people with AMD?
What alternatives to treat
cataracts other than
cataract surgery are
being developed?
Can the treatment of
amblyopia be improved to
produce better short-term
and long-term outcomes
than are possible with
current treatments?
How can the rejection of corneal
transplants be prevented?
What can be done to
improve early
diagnosis of
sight-threatening
glaucoma?
What factors affect the
progression of sight
loss in inherited retinal
diseases?
5 Can the development
of AMD be predicted?
What is the cause of
cataract?
How can cataract be
prevented in children?
Can the outcomes of corneal
transplantation be improved?
What causes
glaucoma?
What causes sight loss
in inherited retinal
diseases?
6 What is the most
effective way to detect
and monitor the
progression of early
AMD?
How can cataract
surgery outcomes be
improved?
What are the causes of
coloboma and
microphthalmia/
anophthalmia and how
can they be prevented?
What causes keratoconus to
progress and can progression be
prevented?
What is the most
effective way of
monitoring the
progression of
glaucoma?
What is the most
effective way to support
patients with inherited
retinal disease?
7 What factors influence
the progression of
AMD?
How safe and effective
is laser assisted cataract
surgery?
Can vision be corrected in
later life for people with
amblyopia?
Can non-surgical therapy be
developed for Fuchs’ corneal
dystrophy?
How can glaucoma
patients with a higher
risk to progress
rapidly be detected?
Can the diagnosis of
inherited retinal
diseases be refined so
that individuals can be
given a clearer idea
about their specific
condition and how it is
likely to progress?
Continued
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Table 3 Continued
Age-related macular
degeneration Cataract
Childhood-onset
disorders Corneal and external diseases Glaucoma
Inherited retinal
diseases
8 Can a non-invasive
therapy be developed
for wet AMD?
Should accommodative
lenses be developed for
cataract surgery?
How can retinoblastoma
be identified, prevented
and treated in children?
Can corneal infections be
prevented in high-risk individuals
such as contact lens wearers?
Why is glaucoma
more aggressive in
people of certain
ethnic groups, such
as those of West
African origin?
What is the relationship
between sight loss and
mental health for people
with inherited retinal
diseases?
9 Can dietary factors,
nutritional
supplements,
complementary
therapies or lifestyle
changes prevent or
slow the progression
of AMD?
What is the best
measure of visual
disability due to
cataract?
Can better treatments for
glaucoma in children be
developed?
What is the cause of keratoconus
and can it be prevented?
How can glaucoma be
prevented?
Would having a
treatment for an
inherited retinal disease
preclude a patient from
having another
treatment?
10 What are the best
enablement strategies
for people with AMD?
Can retinal detachment
be prevented after
cataract surgery?
Can a treatment be
developed to improve
vision for people with
albinism?
What is the most effective
management of ocular
complications associated with
Stevens Johnson Syndrome?
Is there a link
between treatment
adherence and
glaucoma progression
and how can
adherence be
improved?
With regard to inherited
retinal diseases what is
the role of prenatal and
preimplantation
diagnosis in helping
parents make informed
choices?
11 What are the outcomes
for cataract surgery
among people with
different levels of
cognitive impairment (all
causes excluding
dementia, stroke,
neurological conditions,
head injuries)?
Can severe ocular surface
disease in children, such as
blepharokeratoconjunctivitis and
vernal keratoconjunctivitis be
managed better?
Neuro-ophthalmology Ocular cancer
Ocular
inflammatory
diseases
Refractive error and ocular
motility
Retinal vascular
diseases
Vitreoretinal and
ocular trauma
1 What is the underlying cause of
optic nerve damage in optic
neuropathies, such as anterior
ischaemic optic neuropathy,
Leber’s hereditary optic
neuropathy, optic neuritis and
other optic neuropathies?
What can be done to
help ocular cancer
sufferers?
What are the most
effective treatments
for ocular and orbital
inflammatory
diseases?
What factors influence the
development of refractive error
(myopia, astigmatism,
presbyopia and
long-sightedness)?
What are the best
methods to prevent
retinopathy of
prematurity?
How can surgical
techniques be
improved to save
sight for eyes
damaged by injury?
Continued
Row
e
F,etal.BM
J
Open
2014;4:e004905.doi:10.1136/bm
jopen-2014-004905
7
O
p
e
n
A
c
c
e
s
s
Table 3 Continued
Neuro-ophthalmology Ocular cancer
Ocular
inflammatory
diseases
Refractive error and ocular
motility
Retinal vascular
diseases
Vitreoretinal and
ocular trauma
2 What are the most effective
treatments and rehabilitation for
optic neuropathies, eg, Leber’s
hereditary optic neuropathy and
anterior ischaemic optic
neuropathy?
Can gene-based
targeted therapies for
ocular cancers be
developed?
What causes thyroid
eye disease?
What is the cause of both
congenital and acquired
nystagmus?
How can sight loss
from diabetic retinal
changes be prevented
and reduced?
How can the risk of
losing sight for
people with retinal
detachment be
reduced?
3 Can vision loss due to optic nerve
diseases such as giant cell
arteritis, Leber’s hereditary optic
neuropathy, optic neuritis and optic
atrophy, be restored, eg, through
gene therapy and stem cell
treatment?
How can
immunotherapy be
used to fight metastatic
ocular melanoma?
Can the severity of
ocular and orbital
inflammatory
disease in an
individual be
predicted?
How can the development of
binocular vision in young
children with squint and
amblyopia be promoted, and
would the same approach
work in older individuals
without inducing intractable
diplopia?
What are the predictive
factors for the
progression to sight
threatening diabetic eye
disease?
How can better
interventions be
developed that are
effective in treating
vitreous opacities/
eye floaters?
4 What rehabilitation or treatment
methods are most effective for
vision loss following brain damage
due to stroke, brain injury, cerebral
vision impairment, tumours and
dementias?
What are the most
effective detection and
screening methods for
follow-up to detect
metastasis of ocular
melanoma?
Is it possible to
prevent further
occurrences of
retinal damage
caused by
toxoplasmosis?
Would correction of refractive
error have a positive impact
on early life learning and
development?
Is there a way to
improve screening of
premature babies for
retinopathy of
prematurity?
What causes retinal
detachment and can
it be prevented?
5 What is the most effective way to
assess vision in patients with
neurological visual impairment ie,
stroke, dementia and cerebral/
cortical visual impairment?
How can follow-up for
ocular complications be
managed in patients
with ocular melanoma?
What causes
birdshot retinopathy?
Does early diagnosis of
refractive error improve
long-term prognosis and
promote faster, more effective
treatment?
Can an effective long
lasting treatment for
diabetic macular
oedema, both
ischaemic and
non-ischaemic, be
developed?
Can more effective
diagnostic tools be
developed for
assessing the
vitreous and eye
floaters?
6 Can the early stages of optic
neuropathy be detected?
What is the best
management of
metastatic choroidal
melanoma?
Why does disease
burn out in patients
with ocular and
orbital inflammatory
diseases?
What is the effect of
congenital nystagmus on
visual and emotional
development?
Can a retinal vein
occlusion be predicted
and prevented?
Can a functioning
prosthetic eye be
developed to
replace an eye
damaged by injury?
7 How can optic neuropathies be
prevented, for example anterior
ischaemic optic neuropathy,
Leber’s hereditary optic
neuropathy, optic neuritis and
other optic neuropathies?
What activates
choroidal melanoma
metastasis in the liver
after the primary
melanoma has been
treated?
Can early detection
methods be
developed for ocular
and orbital
inflammatory
diseases?
What is the most effective
treatment for exotropia and
when should it be delivered?
Can new non-invasive
treatments be
developed to slow
down the progression
of diabetic retinopathy?
How can epiretinal
membrane/fibrosis
be prevented or
treated?
8 Can treatments be developed for
visual field and ocular motility
manifestations following stroke?
Can adjuvant therapies
be developed to treat
ocular melanoma?
What medications
best prevent the
development of eye
disease in Behcets?
How can the functional effects
of surgical treatment for squint
best be assessed?
What are the barriers
that prevent diabetic
patients having regular
eye checks?
Can stem cells be
used to regrow an
eye or part of an
eye?
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In addition to the strengths of our study, we identiﬁed
a number of limitations. We were unable to calculate a
response rate for the survey because of the nature of its
design and implementation. We did not request the
views of ‘pure’ researchers (ie, scientists with no current
clinical practice) as these individuals are intentionally
excluded from the priority setting process by the JLA.
This step is a key feature of the JLA methodology in
which the remit is to provide an opportunity for
patients, carers and clinicians to inﬂuence the research
agenda. We acknowledge this is a different approach but
do not consider their exclusion as a ﬂaw in this process
as we include clinical researchers who did take part
alongside clinicians and the public.
These questions may now be used to encourage
researchers to investigate what is most important to
these groups. We do not know how our research ques-
tions compare with the prioritisation of research areas
by scientists, government agencies or other organisation
research funders. We are unaware of any systematic data
collating such data.
Various organisations in the sector have set out prior-
ities for eye health and eye research in the past, for
example Vision2020UK.7 In addition, organisations
representing the interests of patients/carers and eye
health professionals took part in the process, both in
promoting the survey and being directly involved in pri-
ority setting. Future work to review the SLV-PSP projects
priorities with these organisations could be helpful in
developing an understanding of how these new, patient
and clinician led priorities can inform the sectors
approach to commissioning research and focusing
resources. Organisations in the sector are already
working to review their organisational priorities with the
SLV priorities, and have begun to invite researchers
seeking funding to consider how their proposed
research relates to the SLV priorities.
Similar to other PSP processes, we have provided infor-
mation on our research priorities openly to national
funding organisations and it is envisaged that research
funders will be able to use the list to inform commis-
sioned calls for research and identify which research
applications to response mode funding opportunities
can answer questions that these groups have agreed are
a priority. Furthermore, any questions or uncertainties
not prioritised in this process were submitted to and are
currently available in the UK Database of Uncertainties
about the Effects of Treatments (UK DUETs). Thus,
individuals looking for uncertainties for their research
can access such information directly from the UK
DUETs. This sharing of information contributes to the
quality assurance process of avoiding waste in research.
The SLV-PSP will also help to increase awareness of
why research on sight loss and vision is necessary and
important. It will be used to campaign for the major
funders to invest in sight loss and eye conditions, all of
which are placing increased emphasis on researchers
demonstrating how they have consulted and involved
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the public and patients in the process of developing
their research.
These remain as signiﬁcant goals. For a sector with
around 700 organisations to arrive at any kind of consen-
sus for research priority areas, a process that was genu-
inely consultative, open and engaging to the individuals
whose interests these organisations represent as well as at
an organisational level was recognised as being critical.
For a prioritisation exercise to be useful to the sector it
needs to make sense to funders and statutory bodies, with
responsibilities and interests in these areas, and to
researchers. It was recognised that a prioritisation of
research areas produced by a small group within the
sector would not be credible and would never engage the
support required for it to achieve the goals listed above.
CONCLUSIONS
Following a systematic process of national consultation
and widespread survey of patients, carers and clinicians,
2220 individuals generated 4461 questions. Through a
process of data analysis, interim prioritisation and ﬁnal
workshops, a top 10 or 11 research questions have been
identiﬁed for 12 categories of eye conditions. This is the
ﬁrst time, to our knowledge, that an exercise like this
has been carried out anywhere in the world for sight
loss and vision. Not only is this the most wide ranging
and ambitious JLA priority setting partnership, it also
engaged a diversity of participants and enabled them to
reach consensus together. For the ﬁrst time, we have a
clear idea of what the consumers of eye research—the
patients and the people who care for and treat them—
believe research money should be spent on. It has pro-
vided a focus for research in sight loss and vision and it
is intended that these priorities are used to inform
funders, researchers, clinicians and the public.
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